McKesson reaffirms FY2027 adjusted EPS forecast of $44.20-$45.00
MCK•McKesson reaffirmed its fiscal 2027 adjusted EPS guidance of $44.20 to $45.00 and long-term adjusted EPS growth outlook of 13% to 16%. The reiteration followed an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.
1. Guidance reaffirmed
McKesson maintained its fiscal 2027 adjusted EPS forecast of $44.20 to $45.00 and its long-term adjusted EPS growth outlook of 13% to 16%. The company said further guidance updates are scheduled for its second-quarter fiscal 2027 earnings call on Nov. 4, 2026.
2. CVS partnership
The guidance reiteration followed an agreement in principle to extend McKesson’s pharmaceutical distribution partnership with CVS Health through June 2032.
